^
    19h
    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma (clinicaltrials.gov)
    P2, N=20, Recruiting, University of Colorado, Denver | Initiation date: Dec 2025 --> Dec 2026
    Trial initiation date
    |
    pegylated liposomal doxorubicin
    3d
    Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working (clinicaltrials.gov)
    P2/3, N=73, Active, not recruiting, National Cancer Institute (NCI) | N=190 --> 73 | Trial completion date: Mar 2030 --> Jan 2027
    Enrollment change • Trial completion date
    |
    Lynparza (olaparib) • temozolomide • pazopanib • Yondelis (trabectedin)
    3d
    Immunoreactivity for CD34, Desmin, Keratins, KIT, Alpha-Smooth Muscle Actin, S100, and Vimentin in Malignant Mesenchymal Neoplasms in Guinea Pigs: A Series of 62 Cases From a Single Institution. (PubMed, Vet Med Sci)
    The strong and diffuse staining pattern of desmin and SMA can be very helpful in distinguishing leiomyosarcoma from its spindle cell mimics. A novel finding is that SMA positivity was identified in malignant endothelium. Immunolabelling for CD34 and KIT provides reliable markers for vascular neoplasms and GISTs. Vimentin does not allow to distinguish between different mesenchymal malignancies in guinea pigs. Occasional positivity for keratins and S100 points to potential pitfalls and emphasised the need for a panel of immunohistochemical stains in the investigation of mesenchymal tumours.
    Journal
    |
    CD34 (CD34 molecule) • VIM (Vimentin) • KRT8 (Keratin 8)
    7d
    Epithelioid leiomyosarcoma harboring HMGA2::RAD51B fusion: expanding the spectrum of RAD51B-rearranged uterine sarcoma. (PubMed, Virchows Arch)
    The patient remains disease-free at 4 months. This case expands the molecular spectrum of ELMS and, concomitantly, broadens the emerging morphologic spectrum of RAD51B-rearranged uterine sarcomas, underscoring the diagnostic value of fusion testing in unusual uterine mesenchymal neoplasms.
    Journal
    |
    ER (Estrogen receptor) • RAD51B (RAD51 Paralog B) • HMGA2 (High mobility group AT-hook 2)
    |
    Archer® FusionPlex® Sarcoma kit • FusionPlex® Dx
    9d
    PROSARC-1: Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=110, Recruiting, Oslo University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    9d
    PROSARC-2: Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. (clinicaltrials.gov)
    P2, N=40, Recruiting, Oslo University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    10d
    Carboplatin monotherapy in recurrent uterine leiomyosarcoma with homozygous BRCA2 deletion: a case report. (PubMed, Int Cancer Conf J)
    Although PARP inhibitors have been utilized in BRCA-mutated ULMS, this case underscores the potential efficacy of platinum-based chemotherapy as an alternative treatment strategy. Furthermore, a therapeutic approach integrating platinum-based chemotherapy followed by PARP inhibitor maintenance, similar to that employed in platinum-sensitive ovarian cancer, warrants further investigation.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    carboplatin
    11d
    A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, M.D. Anderson Cancer Center | N=12 --> 18
    Enrollment change
    |
    TSC2 (TSC complex subunit 2) • TSC1 (TSC complex subunit 1)
    |
    gemcitabine • Fyarro (nanoparticle albumin-bound rapamycin)
    14d
    POTENTIATE: Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications (clinicaltrials.gov)
    P1, N=85, Active, not recruiting, Boundless Bio | Recruiting --> Active, not recruiting | N=127 --> 85
    Enrollment closed • Enrollment change • First-in-human
    |
    erlotinib • Lytgobi (futibatinib)
    15d
    A Japanese Multicenter Database Study of Retroperitoneal Sarcoma: Outcomes of Patients Receiving Eribulin Therapy. (PubMed, Asia Pac J Clin Oncol)
    We separately described outcomes and treatment patterns of patients with resectable and unresectable RPS. Our findings suggest that eribulin should be considered a treatment option for unresectable RPS in clinical practice.
    Journal
    |
    CRP (C-reactive protein)
    |
    Halaven (eribulin mesylate)
    16d
    Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Imlygic (talimogene laherparepvec)
    16d
    Real-World Implementation of Next-Generation Sequencing in Sarcoma: Molecular Insights and Therapeutic Outcomes. (PubMed, Med Sci (Basel))
    Genomics-guided therapy in sarcoma is feasible and impactful. Expanding timely access to molecular profiling is essential for advancing precision oncology in the MENA region.
    Retrospective data • Journal • Real-world evidence • Next-generation sequencing • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • EWSR1 (EWS RNA Binding Protein 1) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex)
    |
    TP53 mutation • CDKN2A deletion • RB1 mutation